Tag: MSD

FDA Accepted NDA and Granted Priority Review for Selumetinib

astrazeneca
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) has accepted a New Drug Applicati...

MSD Worldwide Sales Grew 16%

MSD announced third-quarter worldwide sales of $12.4 billion – an increase of 15% compared with the third quarter of 2018; excluding the negative impact from foreign exchange, worldwide sales grew 16%...

MSD and 4D Pharma to Develop Biotherapeutic Products for Vaccines

4D pharma plc, a leading pharmaceutical company in the development of live biotherapeutics, announces that the company has entered into a research collaboration agreement and an option license to use ...

SMC Accepted KEYTRUDA® for First-Line Treatment of Metastatic Squamous NSCLC

MSD has announced that the Scottish Medicines Consortium (SMC) has accepted KEYTRUDA®▼ (pembrolizumab) in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of metas...

EC Approved KEYTRUDA in Combination with Inlyta

Merck, known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosi...

MSD and Francis Crick Institute to Search Targets for ALS Treatment

Scientists at MSD and the Francis Crick Institute have started a unique new motor neurone disease collaboration to understand the causes and identify potential targets for future treatments. It is co-...

MSD and Themis Bioscience Announce Research Collaboration Agreement

research
Themis Bioscience announced a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclos...

Merck/MSD’s Keytruda Can Be Provided for First-Line Treatment of NSCLC, NICE Stated

Merck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell lung cancer (NSCLC) as part of a regimen with chemotherapy, says NICE. Draft guidanc...

AstraZeneca and MSD’s Announced Positive Results from the Phase III Trial of Lynparza

preclinical-research
AstraZeneca and MSD Inc., Kenilworth, N.J., US announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) w...

FDA to Review Six sBLAs for KEYTRUDA

Merck
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review six supplemental Biologics License Applications (sBLA...

IBM, KPMG, MSD, and Walmart Take Part in FDA Pilot Program

fda
IBM, KPMG, Merck, and Walmart announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the U.S. Drug Supply Cha...

AstraZeneca and MSD’s Lynparza Doubled Progression-Free Survival in Pancreatic Cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced detailed results from the Phase III POLO trial at the 2019 American Societ...

Local Indian Pharma Companies to Challenge MNCs in Pneumonia Vaccine

The duopoly of pneumonia vaccines in India is in for some shake-up soon, as homegrown players like Aurobindo Pharma, Cadila Healthcare (Zydus Cadila), and Serum Institute are readying their vaccin...

ThiIrd Lynparza Indication in EU

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib) as a monotherapy ...

BTD for AstraZeneca and Merck Med

AstraZeneca and MSD, Inc., Kenilworth, NJ, US announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new me...

MSD and Instituto Butantan to collaborate on dengue vaccine

merck
MSD and Instituto Butantan, a non-profit producer of immunobiologic products announced a collaboration agreement to develop vaccines against dengue virus disease, the mosquito-borne infection.